Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF)
- 16 November 2007
- journal article
- retracted article
- Published by Wiley in International Journal of Cancer
- Vol. 122 (2), 461-467
- https://doi.org/10.1002/ijc.23107
Abstract
Serum vitamin D3‐binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum α‐N‐acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized β‐galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16–22 administrations (approximately 3.5–5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.Keywords
Funding Information
- US Public Health Service (AI-32140)
- Elsa U. Pardee Foundation
This publication has 38 references indexed in Scilit:
- Pathogenic Significance ofα-N-Acetylgalactosaminidase Activity Found in the Envelope Glycoprotein gp160 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2006
- Les colles: de la moule au tubeBiofutur, 1998
- Structurally well‐defined macrophage activating factor derived from vitamin D3‐binding protein has a potent adjuvant activity for immunizationImmunology & Cell Biology, 1998
- Multi-subtype FIV vaccineBiofutur, 1997
- Macrophage tumoricidal mechanismsResearch in Immunology, 1993
- The macrophage response to infectious agents: mechanisms of macrophage activation and tumour cell killingResearch in Immunology, 1993
- Breast Cancer Care in Old Age: What We Know, Don't Know, and DoJNCI Journal of the National Cancer Institute, 1993
- Activation process of macrophages afterin vitrotreatment of mouse lymphocytes with dodecylglycerolClinical and Experimental Immunology, 1990
- Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survivalCancer, 1989
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976